Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

81. The effect of mindfulness-based interventions on irritable bowel syndrome: a systematic review and meta-analysis

The effect of mindfulness-based interventions on irritable bowel syndrome: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

82. The risk of depression in Irritable Bowel Syndrome patients: systematic review and meta-analysis

The risk of depression in Irritable Bowel Syndrome patients: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

83. The role of diet in the treatment of the irritable bowel syndrome-a systematic review

The role of diet in the treatment of the irritable bowel syndrome-a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

84. Irritable bowel syndrome and body mass index: a systematic review and meta-analysis

Irritable bowel syndrome and body mass index: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

85. Postinfectious irritable bowel syndrome: a systematic review of prevalence and risk factors for specific pathogens

Postinfectious irritable bowel syndrome: a systematic review of prevalence and risk factors for specific pathogens Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

89. Biofeedback for treatment of irritable bowel syndrome [Cochrane protocol]

Biofeedback for treatment of irritable bowel syndrome [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

90. Immune characteristics of patients with functional dyspepsia and irritable bowel syndrome: a systematic review

Immune characteristics of patients with functional dyspepsia and irritable bowel syndrome: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

91. Mind-body interventions for irritable bowel syndrome patients: systematic review and meta-analysis

Mind-body interventions for irritable bowel syndrome patients: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

92. Mind-body interventions for irritable bowel syndrome patients: systematic review and meta-analysis

Mind-body interventions for irritable bowel syndrome patients: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

93. Effects and safety of interventions for irritable bowel syndrome: overview of systematic reviews

Effects and safety of interventions for irritable bowel syndrome: overview of systematic reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

94. Irritable bowel syndrome

Irritable bowel syndrome Irritable bowel syndrome - NICE CKS Share Irritable bowel syndrome: Summary Irritable bowel syndrome (IBS) is a chronic, relapsing, and often lifelong disorder of the lower gastrointestinal tract, with no discernible structural or biochemical cause. Typical clinical features are abdominal pain: Associated with a change in stool form and/or frequency. Which may be related to defaecation, and there may be associated bloating. The exact underlying cause of IBS is unknown (...) symptoms, specialist referral may be appropriate to: A gastroenterologist for further investigation. A dietitian for specialist advice on single food avoidance and exclusion diets. Mental health services for psychological support and intervention. Have I got the right topic? Have I got the right topic? From age 18 years onwards. This CKS topic covers the management of irritable bowel syndrome in adults in primary care. There are separate CKS topics on , , , , and . The target audience for this CKS

2017 NICE Clinical Knowledge Summaries

95. Herbal Medicines for the Management of Irritable Bowel Syndrome: A Systematic Review. Full Text available with Trip Pro

Herbal Medicines for the Management of Irritable Bowel Syndrome: A Systematic Review. Irritable Bowel Syndrome (IBS) is a chronic digestive disorder, which is characterized by abdominal pain, bloating, diarrhea and constipation periods. The etiology is unknown. Based on the different mechanisms in the etiology, treatment focuses on controlling symptoms. Due to the longtime of syndrome, inadequacy of current treatments, financial burden for patients and pharmacologic effects, several patients

2016 Electronic physician

96. Truberzi (eluxadoline) - for the treatment of adults who have irritable bowel syndrome with diarrhoea

Truberzi (eluxadoline) - for the treatment of adults who have irritable bowel syndrome with diarrhoea 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 21 July 2016 EMA/549473/2016 Committee for Medicinal Products for Human Use (...) index BSS Bristol Stool Scale CHMP Committee for Medicinal Products for Human Use Cmax maximum observed plasma concentration CNS central nervous system CSR clinical study report EMA European Medicines Agency EU European Union FDA US Food and Drug Administration GERD gastroesophageal reflux disease GI gastrointestinal IBS irritable bowel syndrome IBS-d diarrhea-predominant irritable bowel syndrome IBS-m irritable bowel syndrome, where a mixture of constipation and diarrhea is predominant IBS-QoL

2016 European Medicines Agency - EPARs

97. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women Full Text available with Trip Pro

Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women Previous studies have indicated that serotonin-3-receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron

2016 EvidenceUpdates Controlled trial quality: predicted high

98. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome Full Text available with Trip Pro

Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome Irritable bowel syndrome (IBS) affects a large number of children throughout the world. The symptom expression of IBS is heterogeneous, and several factors which may be interrelated within the IBS biopsychosocial model play a role. These factors include visceral hyperalgesia, intestinal permeability, gut microbiota, psychosocial distress, gut inflammation, bile acids, food intolerance, colonic bacterial

2016 Molecular and cellular pediatrics

99. Genetics of irritable bowel syndrome Full Text available with Trip Pro

Genetics of irritable bowel syndrome Irritable bowel syndrome (IBS) is a common condition with a complex and largely unknown etiology. There is no cure, and treatment options are mainly directed to the amelioration of symptoms. IBS causes reduced quality of life and poses considerable repercussions on health and socioeconomic systems. There is a heritable component in IBS, and genetic research is a valuable tool for the identification of causative pathways, which will provide important insight

2016 Molecular and cellular pediatrics

100. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. Full Text available with Trip Pro

Eluxadoline for Irritable Bowel Syndrome with Diarrhea. Background Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea. We conducted two phase 3 trials to assess the efficacy and safety of eluxadoline, a new oral agent with mixed opioid effects (μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist), in patients with IBS with diarrhea. Methods We randomly assigned 2427 adults who had IBS with diarrhea to eluxadoline (at a dose

2016 NEJM Controlled trial quality: predicted high